Currently we operate in emerging markets with our distribution partners and in house brands.
We are open for Out Licensing / Co-development / other models of collaboration, as we expand our footprints to highly regulated markets.
We at Sanzyme are fully aware and prepared of dynamic regulatory landscape in the segment of Biologics/Biosimilars.
Armed with EU GMP & PIC/s for our Finished Formulations, we offer our e-CTD to cater to global regulatory requirements.
Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Yamini Prasad (yaminiprasad.kandru@sanzyme.com) and Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Pundeep Chaparala (pundeep.chaparala@sanzyme.com) and Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
When it comes to human reproduction, hormones play a crucial role in regulating fertility and reproductive health. One of the most important of these is
When it comes to infertility treatments, advancements in reproductive medicine have given many individuals and couples renewed hope. One such advancement is the use of
Since 1969, when we entered into a Joint Venture with Sankyo (now Daiichi-Sankyo) to make gonadotropins to export to Japan, we’ve been at the forefront of biological hormones, and today we have the necessary technological foundation to do path breaking work.
